Analysis of the efficacy, side effects and clinical application of Apremilast (Otelor) tablets

1. Drug Overview and Mechanism of Action

Apremilast is an oral small molecule phosphodiesterase 4 (PDE4) inhibitor, mainly used to treat moderate to severe psoriasis (Psoriasis vulgaris), psoriatic arthritis (PsA) and related inflammatory diseases. Its mechanism of action is to regulate the inflammatory factor network by inhibiting PDE4enzyme activity and increasing intracellular cyclic adenosine monophosphate (cAMP) levels. cAMPElevation can downregulate pro-inflammatory factors such as TNF-α, IL-17< span>, IL-23, etc., while upregulating the anti-inflammatory factor IL-10, reducing the inflammatory response, and improving the symptoms of psoriasis and arthritis. Because it is an oral small molecule drug, it has advantages over biological agents such as convenient administration, high compliance, and no need for injections or cold chain storage.

2. Efficacy and indications

Apremilast tablets are mainly used for the following clinical indications:

Moderate-to-severe plaque psoriasis: For adults who have not responded well to traditional topical therapies or phototherapy. Clinical studies have shown that after 16 weeks of continuous use, the body's anti-aging effects are about 30% to 40% patients can achieve PASI75 (Psoriasis Area and Severity Index Improvement 75%), and skin erythema, scales and thickness are significantly improved.

Psoriatic arthritis (PsA): It is suitable for patients with active arthritis. It can reduce joint pain, swelling and morning stiffness, while improving the patient's quality of life. Randomized controlled trials show that about 40% of patients achieve ACR20 (American College of Rheumatology arthritis improvement standard 20%) within 16 weeks, and the efficacy is stable and sustained.

In addition, apremilast performs well in relieving skin itching, improving skin lesions, and controlling systemic inflammation, and is an important oral option in systemic treatment options.

3. Adverse reactions and safety

Apremilast is generally well tolerated, but common adverse reactions include gastrointestinal symptoms (diarrhea, nausea, indigestion), headache, upper respiratory tract infection, weight loss, etc., most of which are mild to moderate and tolerable. Some patients may experience transient gastrointestinal discomfort in the early stages of treatment, which can generally be relieved with dose adjustment or continued medication. Serious adverse events are rare, but attention should be paid to mental and psychological changes, such as depressive symptoms and low mood, especially patients with a history of mental illness should be closely monitored. Clinically, it is recommended to regularly evaluate blood routine, liver function and weight changes to ensure long-term medication safety.

4. Clinical application and medication management

The standard starting dose of apremilast tablets is usually 10mg to 30mg and is gradually increased to reduce gastrointestinal adverse reactions. The maintenance dose is 30mg twice daily. Patients should regularly follow up with their doctor during the medication period to evaluate skin lesions, joint symptoms and adverse reactions, and adjust medication according to efficacy and tolerability. For patients with mild to moderate symptoms, it can also be used in combination with topical drugs or phototherapy to speed up the improvement of the condition.

In real-world applications, apremilast has become the preferred option for patients who are intolerant to injectable biologics or wish to avoid injections due to its convenience and high safety. Clinical observations show that long-term use can maintain stable improvement in skin and joint symptoms without increasing the risk of serious infection or immunosuppression.

5. Comparison with other treatment options

Compared with traditional immunosuppressants (such as cyclosporine and methotrexate), apremilast has milder side effects and does not require frequent blood monitoring or liver and kidney function tests. Compared with biological agents, its oral administration has obvious advantages, but in some patients, the achievement rate of PASI90 or ACR50 is slightly lower. Overall, it strikes a balance between efficacy, convenience and safety, and is particularly suitable for patients with high long-term management and compliance requirements.

Apremilast tablets are an innovative oral PDE4 inhibitor that improves the symptoms of psoriasis and psoriatic arthritis by regulating inflammatory factors. It has shown significant efficacy in moderate to severe psoriasis and active arthritis, with controllable adverse reactions and high safety. In clinical application, it can be used alone or combined with local treatment to meet the individual treatment needs of different patients. With its oral administration, good tolerance and long-term safety, apremilast has become an important choice for systemic treatment of psoriasis, providing patients with a more convenient and safe management solution.

Reference materials:https://www.drugs.com/